Jülich-based SRTD Biotech secures €31.5 million to develop precision mRNA therapies targeting diseased cells
SRTD Biotech, a Jülich-based BioTech startup focused on developing next-generation precision mRNA therapeutics, has completed an oversubscribed €31.5 million Seed financing round. The funding was led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund joining the syndicat
<p>SRTD Biotech, a Jülich-based BioTech startup focused on developing next-generation precision mRNA therapeutics, has completed an oversubscribed €31.5 million Seed financing round. The funding was led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund joining the syndicat</p>